FDA Brief

Warning letters Drugs

FDA warning letter to

HIS Enterprise Inc dba Adam’s Secret USA, LLC

High riskIssued Jan 10, 2023Posted Jan 17, 2023Center for Drug Evaluation and Research | CDER

FDA: Adam's Secret and Dr. Reade Slim Sense supplements sold online contain hidden prescription drugs tadalafil, sildenafil and lorcaserin.

What happened

FDA reviewed the company's website, www.adamssecret.com, in May 2022 and again in December 2022, along with its Instagram and Facebook pages, and obtained samples and labeling of the products. Laboratory analysis confirmed that the Adam's Secret products contained undeclared tadalafil and/or sildenafil (the active ingredients in the prescription drugs Cialis and Viagra), and that Dr. Reade Slim Sense contained undeclared lorcaserin, the active ingredient in the withdrawn weight-loss drug Belviq. There was no inspection; the findings came from the website review and product testing.

What FDA found

  1. Samples of the Adam's Secret products contained tadalafil and/or sildenafil, the active ingredients in the prescription erectile-dysfunction drugs Cialis and Viagra, and the labels did not disclose them.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  2. A sample of Dr. Reade Slim Sense contained lorcaserin, the active ingredient in the withdrawn prescription weight-loss drug Belviq, and the label did not disclose it.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  3. The products are unapproved new drugs because they are promoted to treat erectile dysfunction and to cause weight loss, and no FDA-approved application is in effect for them.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. Because they contain tadalafil, sildenafil or lorcaserin, the products are excluded from the legal definition of a dietary supplement.

    FD&C Act section 201(ff)(3)(B)(i) and (ii), 21 U.S.C. 321(ff)(3)(B)
  5. The labels do not give adequate directions for use, which is impossible for a prescription drug sold without an approved application.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5, 201.100(c)(2), 201.115
  6. The labels lack adequate warnings for users, who would not know they are taking a PDE-5 inhibitor or lorcaserin.

    FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2)

What FDA wants

FDA asks the company to send a written response within fifteen working days of receiving the letter, explaining each step taken to fix the violations and to prevent them from recurring, with supporting documents. If the company believes the products are not in violation, it must send its reasoning and supporting information in the same period.

Who should pay attention

  • online sellers of erectile-dysfunction or weight-loss supplements
  • retailers and marketplaces that list 'natural' sexual enhancement or slimming pills
  • brands that buy finished supplement products from outside contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk